Venn Life Sciences, a growing Clinical Research Organization providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European Clinical Research Organizations.
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organization (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European Clinical Research Organizations. Venn acquired German CRO CRM clinical trials and Medevol Clinical Services in the UK.
Founded in 1996, CRM is a full-service CRO based in Rheinbach, Germany, specializing in Phases II-IV. In addition to extensive experience in dermatology, pneumology and urology, the CRM team have considerable expertise in conducting clinical trials in the field of sports medicine, as well as in the running of non-interventional studies. CRM also serves the Austrian and Italian regions and gives the combined organisation a ready-made and robust base of business with an expanded group of regular clients from some of the world’s leading pharmaceutical, biotechnology, and medical devices companies.
CRM’s suite of services include initial and ongoing training for study nurses, investigators and trial teams in the areas of quality, planning and monitoring of clinical studies. The company has worked closely with Government agencies to ensure that the courses they undertake, particularly for Study Nurses, provide a full understanding of protocols and protects the rights, safety and well-being of the trial subjects, which then assures the credibility of the clinical trial data generated.
Medevol has been an active CRO in the UK clinical trials market since 2001, conducting full-service studies for global pharmaceutical and biotechnology companies across Phases II - IV. With extensive therapeutic experience across a broad range of indications, Medevol also provide contract staffing solutions, offering companies the flexibility to manage different levels of resourcing needs throughout the clinical trial process. Based in Belfast, Medevol complements Venn’s UK clinical operations with their valued history and investigator contacts throughout the UK.
These two additions to Venn’s European operations bring a common leading global client with ongoing and future projects booked. Venn can now offer its clients enhanced services and experience in the management, resourcing and conducting of clinical trials in Europe.
Commenting on the acquisitions, Tony Richardson, CEO of Venn, said: “The addition of these two offices to Venn’s European operations further aligns our actions to our overall strategy of becoming a leading mid-sized European CRO. The skills and talent that we are adding to our company enhance our reputation as a CRO that stays close to its clients, guiding them through the often complicated process of conducting trials across Europe. We as a company are also looking at adding to these acquisitions over the coming months and increasing our office locations across Europe”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.